Nab-paclitaxel as second-line treatment in advanced biliary cancer

被引：0
|
作者：
Unseld, M. [1 ]
Kornek, G. [2 ]
Werner, S. [2 ]
Guenther, S. [2 ]
Christoph, Z.
Gerald, P.
机构：
[1] Med Univ Vienna, Oncol, Vienna, Austria
[2] MUW, Oncol, Vienna, Austria
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31215-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2299
引用
收藏
页码：S431 / S432
页数：2
相关论文
共 50 条
  • [31] Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer
    Iede, Kiyotsugu
    Yamada, Terumasa
    Kato, Ryo
    Ueda, Masami
    Tsuda, Yujiro
    Nakashima, Shinsuke
    Ohta, Katsuya
    Matsuyama, Jin
    Ikenaga, Masakazu
    Tominaga, Shusei
    CANCER REPORTS, 2020, 3 (02)
  • [32] Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer
    Wong, Wenjing
    Sun, Ping
    Mu, Zhengbin
    Liu, Jiannan
    Yu, Caiyan
    Liu, Aina
    ANTICANCER RESEARCH, 2017, 37 (08) : 4687 - 4691
  • [33] Nab-paclitaxel plus anti-PD-1 antibody as second-line treatment for advanced biliary tract cancer: An investigator-initiated phase 2 study (NapaSinti trial).
    Li, Xiaofen
    Zhou, Nan
    Yang, Yu
    Gou, Hongfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 564 - 564
  • [34] Study on the efficacy and safety of sintilimab combined with nab-paclitaxel as second-line treatment for advanced or metastatic gastric cancer (GC)/ gastroesophageal junction (GEJ) cancer.
    Wang, Jianzheng
    He, Yunduan
    Zhang, Baiwen
    Cheng, Xiaojiao
    Li, Qingli
    Lv, Huifang
    Nie, Caiyun
    Chen, Beibei
    Xu, Weifeng
    Zhao, Jing
    Tu, Shuiping
    Chen, Xiaobing
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16016 - E16016
  • [35] Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer
    Kokkali, Stefania
    Tripodaki, Elli-Sophia
    Drizou, Maria
    Stefanou, Dimitra
    Magou, Elpida
    Zylis, Dimosthenis
    Kapiris, Matthaios
    Nasi, Despoina
    Georganta, Chara
    Ardavanis, Alexandros
    IN VIVO, 2018, 32 (03): : 653 - 657
  • [36] Gemcitabine and nab-paclitaxel retreatment as a third-line therapy following second-line FOLFIRINOX for advanced pancreatic adenocarcinoma.
    Dean, Andrew Peter
    Das, Adarsh
    McNulty, Meabh
    Higgs, Domenic
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] Nab-Paclitaxel ± CC-486 as Second-Line Treatment of Advanced NSCLC: Results from the ABOUND.2L+Study
    Morgensztern, D.
    Cobo Dols, M.
    Ponce Aix, S.
    Postmus, P. E.
    Bennouna, J.
    Fischer, J.
    Vidal, O.
    Stewart, D.
    Fasola, G.
    Weaver, J.
    Wolfsteiner, M.
    Ong, T. J.
    Govindan, R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1806 - S1807
  • [38] nab-Paclitaxel for the treatment of pancreatic cancer
    Kim, George
    CANCER MANAGEMENT AND RESEARCH, 2017, 9 : 85 - 96
  • [39] Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
    Chiorean, E. Gabriela
    Von Hoff, Daniel D.
    Tabernero, Josep
    El-Maraghi, Robert
    Ma, Wen Wee
    Reni, Michele
    Harris, Marion
    Whorf, Robert
    Liu, Helen
    Li, Jack Shiansong
    Manax, Victoria
    Romano, Alfredo
    Lu, Brian
    Goldstein, David
    BRITISH JOURNAL OF CANCER, 2016, 115 (02) : 188 - 194
  • [40] Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
    E Gabriela Chiorean
    Daniel D Von Hoff
    Josep Tabernero
    Robert El-Maraghi
    Wen Wee Ma
    Michele Reni
    Marion Harris
    Robert Whorf
    Helen Liu
    Jack Shiansong Li
    Victoria Manax
    Alfredo Romano
    Brian Lu
    David Goldstein
    British Journal of Cancer, 2016, 115 : 188 - 194
12345